Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07185893Not ApplicableNot Yet Recruiting

A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors

Role: lead

NCT06178146Phase 4Unknown

Thymosin Alpha-1 for irAE Secondary to ICIs

Role: lead

NCT04111328Phase 4Completed

the Effect of Different Drugs and Infusion Ways on Degree of Postoperative Comfort

Role: lead

NCT04692935Unknown

Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis

Role: lead

All 4 trials loaded